Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05572177
Other study ID # STUDY000956
Secondary ID R34HL145442
Status Recruiting
Phase N/A
First received
Last updated
Start date June 20, 2023
Est. completion date May 2024

Study information

Verified date December 2023
Source University of South Florida
Contact Dipti Karnani
Phone 813-974-5193
Email diptik@usf.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary goal of this project is to determine the feasibility, acceptability, and adherence of a smartphone application for improving asthma self-management in a pilot randomized controlled trial (RCT). The app is specifically designed to appeal to adolescents. Adolescents with persistent asthma will be randomized to receive: 1) standard-of-care or 2) the self-management app in addition to standard-of-care. Feasibility will be assessed by the ability to recruit and retain subjects, technical barriers to implementation, and the appropriateness of the intervention among adolescents and providers. The acceptability of the intervention will be determined by appraising perceived usefulness, entertainment, and ease of use of the app. Adherence to usage of the app over a 6-month period will be assessed by examining the frequency of app usage and the features that were used, and the extent of data regarding self-management that was entered. A secondary objective is to obtain preliminary estimates of effectiveness of the app on clinical outcomes (ACT score, spirometry, CHSA-C, exacerbations, and medication adherence) relative to standard-of-care. It is hypothesized that the app will result in a high level of adherence and will be a feasible and acceptable intervention to improve self-management among adolescents with persistent asthma.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date May 2024
Est. primary completion date May 2024
Accepts healthy volunteers No
Gender All
Age group 12 Years to 17 Years
Eligibility Inclusion Criteria: - At least 12 and less than 18 years at enrollment - Established mild, moderate, or severe persistent asthma with a diagnosis verified by clinic physicians - Speak English - Not planning on moving out of the Tampa Bay area during the trial period - Must have a suitable iPhone or Android device available to use with the app Exclusion Criteria: - Having mental or other development disorder that may make self-management of a chronic condition difficult - Having other chronic lung disease or one or more of the following disorders including cystic fibrosis, neuromuscular disease, immunodeficiency or autoimmune disorders, blindness or severe vision impairment that may interfere with the ability to use the mobile app - Having participated in the app development phase of the funded project

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Asthma SMART
The intervention is a smartphone application to improve self-management of asthma designed to appeal to adolescents. The app integrates four components to facilitate asthma self-management: 1) self-monitoring of peak-flow and symptoms; 2) graphical health user interfaces with avatars, infographics, and rewards; 3) interactive educational materials; and 4) patient-provider interactions.

Locations

Country Name City State
United States University of South Florida Tampa Florida

Sponsors (2)

Lead Sponsor Collaborator
University of South Florida National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recruitment rate (number recruited per month) The recruitment rate will be defined as the total number of participants recruited divided by the number of months of recruitment to determine the approximate number of participants recruited in a single site per month. 6 months
Primary Retention rate (proportion that complete the 6-month trial) The retention rate will be calculated as the number of participants that complete the 6 month follow-up exam divided by the total number of participants randomized in the study. 6 months
Primary Technical feasibility (percentage of screened population) The percentage of the screened population that has a suitable smartphone and data plan or wi-fi access in order to use the app. 6 months
Primary Mean overall usability score obtained from the Health-ITUES The Health Information Technology Usability Evaluation Scale is a validated survey of usability of mobile health technology consisting of 20 questions each on a 5-point Likert scale with four subscale domains on impact, perceived usefulness, perceived ease of use, and user control. The total score is calculated as the average score across the domains with a value range from 1 to 5. Higher scores represent greater usability. Assessed at the end of the 6 month trial
Primary Average app usage per day Sustainability of app usage will be defined as the number of days each participant interacted with the app at least once divided by the total number of days in the trial. Interaction is defined as performing any activity in the app. 6 months
Primary Adherence to app reminders (proportion of app reminders) Adherence to the app will be determined by examining the frequency of responses to app reminders. Adherence will be calculated as the number of activities completed in response to an app reminder divided by the total number of reminders received. 6 months
Secondary Change in ACT score from baseline to the 6-month end point The ACT test is a validated 5-question survey used to measure asthma control according to NHLBI guidelines. Total scores range from 5 to 25. Change will be calculated as the 6-month ACT score - baseline ACT score. Baseline and 6 month end-point
See also
  Status Clinical Trial Phase
Recruiting NCT04438408 - National Survey on Care Pathway and Quality of Life in Patients With Severe Asthma According to Their Phenotype.
Recruiting NCT04693975 - Social Distancing During the COVID-19 Pandemic and People Living With Chronic Respiratory Diseases
Completed NCT04456270 - Asthma Control in a Dutch Primary Care Population
Active, not recruiting NCT04593394 - Inducible Laryngeal Obstruction in Severe Asthma in Severe Asthma
Not yet recruiting NCT06364527 - Use of Aptar Digital Health's Respiratory Disease Management Platform for Asthma N/A
Not yet recruiting NCT03879590 - Efficacy Of Doxophylline As A Sparing Treatment For Inhaled Corticosteroids In Mexican Children With Asthma Phase 3
Recruiting NCT04613245 - Health-Related Quality of Life of Patients With Asthma During the Pandemic of COVID-19
Withdrawn NCT05304494 - Sentinel - Triaging Acute Breathlessness Using Multi-Modal Biomarkers
Completed NCT03498742 - Asthmatic Subjects Could Live Without Short Acting beta2 Agonists
Not yet recruiting NCT05841901 - Huang-long Zhi-xiao Granule Improves the Control Rate of Chronic Persistent of Asthma N/A
Not yet recruiting NCT04799678 - Pilot Voice Sample Collection From People With Asthma
Not yet recruiting NCT06273072 - Metformin IN Asthma for Overweight and Obese Individuals (MINA) Phase 2
Terminated NCT03736629 - Azithromycin Treatment for the Airway Microbiome in Asthma Phase 2
Recruiting NCT03788057 - Inflammatory Indices in Predicting the Failure of Inhaled Corticosteroids Reduction in Young Participants With Asthma N/A
Not yet recruiting NCT02283008 - Inhaler Technique Training N/A
Completed NCT02227394 - Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic Patients Phase 2
Not yet recruiting NCT05432440 - Evaluation of Pharmacist-guided Digital-based Asthma Education for Indonesian Children With Asthma N/A
Completed NCT05270278 - Characteristics of Type 2- High Inflammatory Endotype of Asthma Using New Biomarkers From Peripheral Blood and Exhaled Air and Its Effect on the Outcome of Therapy
Completed NCT03642418 - User-Friendly Spirometer and Mobile App for Self-Management and Home Monitoring of Asthma Patients
Recruiting NCT05609760 - Pictograms to Facilitate Comprehension of Medical Indications N/A